Please ensure Javascript is enabled for purposes of website accessibility
Cory Renauer

Cory Renauer


Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.

Recent articles


Why BioCryst Pharmaceuticals Rose 8% on Thursday

The company's first commercial drug launch keeps exceeding expectations.


Here's Why Ampio Pharmaceuticals Stock Is Surging Today

A positive second-quarter earnings report and anticipation of further details to be discussed this afternoon helped this beaten-down biotech stock recover some previous losses.


3 Unstoppable Healthcare Stocks to Buy Now and Hold Forever

Here are some terrific options for investors who just want to set it and forget it.


3 High-Growth Healthcare Stocks to Buy in August

These potential stock rockets are well worth the different risks they present.


Here's Why TG Therapeutics Stock Is Getting Hammered Today

A second-quarter earnings report reminded investors how difficult it is for independent companies to launch new cancer drugs.


Here's Why Autolus Therapeutics Is Surging Today

Potential licensing agreements with Moderna are giving investors reasons to cheer.


Is Align Technology a Buy After a Blowout Second Quarter?

The leading provider of clear aligners is firing on all cylinders right now.


Here's Why Novocure Dipped 19% This Week

Uptake of the company's revolutionary disease-controlling device isn't progressing as quickly as expected.


Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.


Can Teladoc Health Stock Start Climbing Again?

Slowing growth in the face of exploding competition for digital health services should have investors more than a little concerned.


Here's Why Myovant Sciences Stock Is Falling Today

Second-quarter earnings results were a little bit disappointing.


Here's Why Relmada Therapeutics Stock Popped Today

Results from a human abuse potential study with REL-1017 exceeded expectations.


Here's Why NRx Pharmaceuticals Stock Dropped Monday

After soaring for a couple of days this popular COVID-19 stock fell back.


2 Beaten-Down Biotech Stocks That Could Bounce Back

The market hasn't been kind to these two drugmakers, but both have a chance to turn things around.


3 Biotech Stocks That Could Rocket Higher

Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.


Here's Why Alzamend Neuro Stock Is Shooting Higher Today

There's never been a better time to be a mouse with Alzheimer's disease.


Here's Why Cassava Sciences Is Surging Today

Investors are excited about upcoming presentations scheduled for the annual Alzheimer's Association International Conference.


3 Biotech Stocks That Could Double Soon

Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.


Here's Why Cytokinetics Is Rocketing Higher Today

The company's new heart drug candidate produced encouraging clinical trial results.


3 Stocks to Buy in the Upcoming Market Crash

Recurring revenue and network effects make these terrific stocks to buy on the dips.